Gontivimab (1-68 mg/kg; intranasal administration or nebulization) reduces the RSV load in the nose and lungs in rats[1].
According to the laws, regulations and policies related to "patent products", the sale of this product is prohibited!
ChemicalBook prompt
The patent owner or licensee of the product has not released any relevant information for the time being.
Product Name*
CAS.No
Inquiry Amount*
Port*
Inquiry Description*
+Add Attachment (File Format: Jpg, Gif, Png, PDF,Zip,Txt,doc or xls Max Size: 3MB)
Remove